Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The world's first mRNA vaccine against Elephant Endotheliotropic Herpesvirus (EEHV) has reportedly shown promising results, ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Vaccines have been rigorously tested, reviewed, and monitored for decades. They are one of the greatest success stories in ...

The US Advisory Committee on Immunization Practices voted in June to stop recommending certain kinds of flu vaccines, a ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines.

Messenger RNA (mRNA) vaccines hold promise for creating new and improved immunizations; however, their delivery is challenging in terms of compliance, reactogenicity, cost and scalability.